


See “Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with *NUDT15* heterozygosity” on page 90-100.



Supplementary Fig.1. Flow of the analysis in this study. In total, 210 patients with inflammatory bowel disease (IBD) genotyped for *NUDT15* R139C were enrolled. Among them, 138 patients with C/C or C/T genotype exposed to thiopurines were analyzed for cumulative thiopurine continuation rate (Fig. 1D). Of them, 46 patients with ulcerative colitis (UC) who received thiopurines on maintenance therapy were analyzed for cumulative non-relapse rate (Table 4, Fig. 2), and 69 patients with Crohn's disease (CD) receiving combination therapy with anti- tumor necrosis factor (TNF)- α agents were analyzed for cumulative surgery-free rate (Table 5, Fig. 3).